Literature DB >> 24996573

Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial: design, rationale and implementation.

Sarah Baraniuk1, Barbara C Tilley2, Deborah J del Junco3, Erin E Fox3, Gerald van Belle4, Charles E Wade3, Jeanette M Podbielski3, Angela M Beeler3, John R Hess5, Eileen M Bulger6, Martin A Schreiber7, Kenji Inaba8, Timothy C Fabian9, Jeffrey D Kerby10, Mitchell Jay Cohen11, Christopher N Miller12, Sandro Rizoli13, Thomas M Scalea14, Terence O'Keeffe15, Karen J Brasel16, Bryan A Cotton3, Peter Muskat17, John B Holcomb3.   

Abstract

BACKGROUND: Forty percent of in-hospital deaths among injured patients involve massive truncal haemorrhage. These deaths may be prevented with rapid haemorrhage control and improved resuscitation techniques. The Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial was designed to determine if there is a difference in mortality between subjects who received different ratios of FDA approved blood products. This report describes the design and implementation of PROPPR. STUDY
DESIGN: PROPPR was designed as a randomized, two-group, Phase III trial conducted in subjects with the highest level of trauma activation and predicted to have a massive transfusion. Subjects at 12 North American level 1 trauma centres were randomized into one of two standard transfusion ratio interventions: 1:1:1 or 1:1:2, (plasma, platelets, and red blood cells). Clinical data and serial blood samples were collected under Exception from Informed Consent (EFIC) regulations. Co-primary mortality endpoints of 24h and 30 days were evaluated.
RESULTS: Between August 2012 and December 2013, 680 patients were randomized. The overall median time from admission to randomization was 26min. PROPPR enrolled at higher than expected rates with fewer than expected protocol deviations.
CONCLUSION: PROPPR is the largest randomized study to enrol severely bleeding patients. This study showed that rapidly enrolling and successfully providing randomized blood products to severely injured patients in an EFIC study is feasible. PROPPR was able to achieve these goals by utilizing a collaborative structure and developing successful procedures and design elements that can be part of future trauma studies.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clinical trial; Plasma; Platelets; Resuscitation; Transfusion; Trauma

Mesh:

Year:  2014        PMID: 24996573      PMCID: PMC4137482          DOI: 10.1016/j.injury.2014.06.001

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  36 in total

1.  Challenges to effective research in acute trauma resuscitation: consent and endpoints.

Authors:  John B Holcomb; Richard Weiskopf; Howard Champion; Steven A Gould; R Michelle Sauer; Karen Brasel; Grant Bochicchio; Eileen Bulger; Bryan A Cotton; Daniel Davis; Richard Dutton; Carl J Hauser; John R Hess; George A Hides; Paula Knudson; Ellen MacKenzie; Robert L McGinnis; Joel Michalek; Frederick A Moore; Laurel Omert; Brad H Pollock; Bartholomew Tortella; Jeremy Sugarman; Martin A Schreiber; Charles E Wade
Journal:  Shock       Date:  2011-02       Impact factor: 3.454

2.  Design and preliminary results of a pilot randomized controlled trial on a 1:1:1 transfusion strategy: the trauma formula-driven versus laboratory-guided study.

Authors:  Bartolomeu Nascimento; Sandro Rizoli; Gordon Rubenfeld; Yulia Lin; Jeannie Callum; Homer C Tien
Journal:  J Trauma       Date:  2011-11

Review 3.  Prevalence of survivor bias in observational studies on fresh frozen plasma:erythrocyte ratios in trauma requiring massive transfusion.

Authors:  Anthony M-H Ho; Peter W Dion; Janice H H Yeung; John B Holcomb; Lester A H Critchley; Calvin S H Ng; Manoj K Karmakar; Chi W Cheung; Timothy H Rainer
Journal:  Anesthesiology       Date:  2012-03       Impact factor: 7.892

4.  Impact of policy change on US Army combat transfusion practices.

Authors:  John W Simmons; Christopher E White; Brian J Eastridge; James E Mace; Charles E Wade; Lorne H Blackbourne
Journal:  J Trauma       Date:  2010-07

5.  A multidisciplinary "think tank": the top 10 clinical trial opportunities in transfusion medicine from the National Heart, Lung, and Blood Institute-sponsored 2009 state-of-the-science symposium.

Authors:  Cassandra D Josephson; Simone A Glynn; Steve H Kleinman; Morris A Blajchman
Journal:  Transfusion       Date:  2010-10-04       Impact factor: 3.157

6.  Multicenter validation of a simplified score to predict massive transfusion in trauma.

Authors:  Bryan A Cotton; Lesly A Dossett; Elliott R Haut; Shahid Shafi; Timothy C Nunez; Brigham K Au; Victor Zaydfudim; Marla Johnston; Patrick Arbogast; Pampee P Young
Journal:  J Trauma       Date:  2010-07

7.  Out-of-hospital hypertonic resuscitation after traumatic hypovolemic shock: a randomized, placebo controlled trial.

Authors:  Eileen M Bulger; Susanne May; Jeffery D Kerby; Scott Emerson; Ian G Stiell; Martin A Schreiber; Karen J Brasel; Samuel A Tisherman; Raul Coimbra; Sandro Rizoli; Joseph P Minei; J Steven Hata; George Sopko; David C Evans; David B Hoyt
Journal:  Ann Surg       Date:  2011-03       Impact factor: 12.969

8.  Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage.

Authors:  Carl J Hauser; Kenneth Boffard; Richard Dutton; Gordon R Bernard; Martin A Croce; John B Holcomb; Ari Leppaniemi; Michael Parr; Jean-Louis Vincent; Bartholomew J Tortella; Jeannett Dimsits; Bertil Bouillon
Journal:  J Trauma       Date:  2010-09

9.  Damage control hematology: the impact of a trauma exsanguination protocol on survival and blood product utilization.

Authors:  Bryan A Cotton; Oliver L Gunter; James Isbell; Brigham K Au; Amy M Robertson; John A Morris; Paul St Jacques; Pampee P Young
Journal:  J Trauma       Date:  2008-05

10.  The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks.

Authors:  John B Holcomb; Deborah J del Junco; Erin E Fox; Charles E Wade; Mitchell J Cohen; Martin A Schreiber; Louis H Alarcon; Yu Bai; Karen J Brasel; Eileen M Bulger; Bryan A Cotton; Nena Matijevic; Peter Muskat; John G Myers; Herb A Phelan; Christopher E White; Jiajie Zhang; Mohammad H Rahbar
Journal:  JAMA Surg       Date:  2013-02       Impact factor: 14.766

View more
  42 in total

1.  Cost-effectiveness evaluation of the PROPPR trial transfusion protocols.

Authors:  Rachael A Callcut; Kit N Simpson; Sarah Baraniuk; Erin E Fox; Barbara C Tilley; John B Holcomb
Journal:  Transfusion       Date:  2020-05-01       Impact factor: 3.157

2.  Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial.

Authors:  John B Holcomb; Barbara C Tilley; Sarah Baraniuk; Erin E Fox; Charles E Wade; Jeanette M Podbielski; Deborah J del Junco; Karen J Brasel; Eileen M Bulger; Rachael A Callcut; Mitchell Jay Cohen; Bryan A Cotton; Timothy C Fabian; Kenji Inaba; Jeffrey D Kerby; Peter Muskat; Terence O'Keeffe; Sandro Rizoli; Bryce R H Robinson; Thomas M Scalea; Martin A Schreiber; Deborah M Stein; Jordan A Weinberg; Jeannie L Callum; John R Hess; Nena Matijevic; Christopher N Miller; Jean-Francois Pittet; David B Hoyt; Gail D Pearson; Brian Leroux; Gerald van Belle
Journal:  JAMA       Date:  2015-02-03       Impact factor: 56.272

3.  Hemostatic resuscitation is neither hemostatic nor resuscitative in trauma hemorrhage-But did they in fact test the effect of hemostatic resuscitation?

Authors:  Jakob Stensballe; John B Holcomb
Journal:  J Trauma Acute Care Surg       Date:  2015-06       Impact factor: 3.313

Review 4.  Advances in damage control resuscitation and surgery: implications on the organization of future military field forces.

Authors:  Homer Tien; Andrew Beckett; Naisan Garraway; Max Talbot; Dylan Pannell; Thamer Alabbasi
Journal:  Can J Surg       Date:  2015-06       Impact factor: 2.089

5.  Making thawed universal donor plasma available rapidly for massively bleeding trauma patients: experience from the Pragmatic, Randomized Optimal Platelets and Plasma Ratios (PROPPR) trial.

Authors:  Deborah J Novak; Yu Bai; Rhonda K Cooke; Marisa B Marques; Magali J Fontaine; Jerome L Gottschall; Patricia M Carey; Richard M Scanlan; Eberhard W Fiebig; Ira A Shulman; Janice M Nelson; Sherri Flax; Veda Duncan; Jennifer A Daniel-Johnson; Jeannie L Callum; John B Holcomb; Erin E Fox; Sarah Baraniuk; Barbara C Tilley; Martin A Schreiber; Kenji Inaba; Sandro Rizoli; Jeanette M Podbielski; Bryan A Cotton; John R Hess
Journal:  Transfusion       Date:  2015-03-30       Impact factor: 3.157

6.  Polytrauma management - What is new and what is true in 2020 ?

Authors:  H C Pape; L Leenen
Journal:  J Clin Orthop Trauma       Date:  2020-10-29

7.  Current updates in management of extremity injuries in polytrauma.

Authors:  A Devendra; Gupta Nishith P; S Dilip Chand Raja; J Dheenadhayalan; S Rajasekaran
Journal:  J Clin Orthop Trauma       Date:  2020-09-24

8.  Assessing protocol adherence in a clinical trial with ordered treatment regimens: Quantifying the pragmatic, randomized optimal platelet and plasma ratios (PROPPR) trial experience.

Authors:  Hongjian Zhu; Erin E Fox; Sarah Baraniuk; John B Holcomb; Charles E Wade; Deborah J Del Junco; Barbara C Tilley
Journal:  Injury       Date:  2016-07-21       Impact factor: 2.586

9.  Valproic acid improves survival and decreases resuscitation requirements in a swine model of prolonged damage control resuscitation.

Authors:  Aaron M Williams; Umar F Bhatti; Ben E Biesterveld; Nathan J Graham; Kiril Chtraklin; Jing Zhou; Isabel S Dennahy; Ranganath G Kathawate; Claire A Vercruysse; Rachel M Russo; Yongqing Li; Hasan B Alam
Journal:  J Trauma Acute Care Surg       Date:  2019-08       Impact factor: 3.313

10.  Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial.

Authors:  Jessica C Cardenas; Xu Zhang; Erin E Fox; Bryan A Cotton; John R Hess; Martin A Schreiber; Charles E Wade; John B Holcomb
Journal:  Blood Adv       Date:  2018-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.